How Novartis assesses a drug’s probability of success prior to the pivotal trial

Transitioning a developing compound from early phase clinical trials to a pivotal trial(s) can be a make-or-break decision for a small- or medium-sized pharma. And sometimes companies aren’t very good at making the right decision.

While many companies often rely on outdated ways to assess the probability of any given...

Click to view original post